Hypofractionated concurrent chemoradiation in non-small cell lung cancer (NSCLC): efficacy and toxicity of the SOCCAR trial regime in real world practice

被引：1
作者：
Iqbal, M. S. [1 ]
Vashisht, G. [2 ]
Mulvenna, P. [1 ]
McDonald, F. [1 ]
Turnbull, H. [1 ]
Atherton, P. [1 ]
Bradshaw, A. [1 ]
Simmons, T. [3 ]
Kovarik, J. [1 ]
Singhal, S. [1 ]
McMenemin, R. [3 ]
Greystoke, A. [4 ]
机构：
[1] Northern Ctr Canc Care, Clin Oncol, Newcastle Upon Tyne, Tyne & Wear, England
[2] Newcastle Univ, Med Sch, HH, Newcastle Upon Tyne, Tyne & Wear, England
[3] Freeman Rd Hosp, NCCC, Clin Oncol, Newcastle Upon Tyne, Tyne & Wear, England
[4] NCCC, Med Oncol, Newcastle Upon Tyne, Tyne & Wear, England
来源：
LUNG CANCER | 2018年 / 115卷
关键词：
D O I：
10.1016/S0169-5002(18)30175-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [41] A Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Unresectable Stage III Non-Small Cell Lung Cancer
    Durm, Greg
    Hanna, Nasser
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S569 - S570
  • [42] Impact of age on chemoradiation (CRT) for locally advanced non-small cell lung cancer (NSCLC)
    Dallas, J. L.
    Sullivan, J. E.
    Riggs, C. E.
    Hou, W.
    LaPlant, K. D.
    George, T. J.
    Louzon, P.
    Lynch, J. W.
    Close, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Durvalumab Adjuvant to Chemoradiation for Patients With Locally Advanced Non-Small Cell Lung Cancer: Real World Experience
    Haakensen, V. D.
    Nymoen, H. M.
    Langberg, C. W.
    Horndalsveen, H.
    Farooqi, S.
    Bjaanaes, M.
    Helland, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1045 - S1045
  • [44] Age is no barrier to radical chemoradiation in locally advanced non-small cell lung cancer (NSCLC)
    Gomberg, S.
    Hiley, C.
    Taylor, B.
    Ahmad, S.
    Smith, D.
    LUNG CANCER, 2019, 127 : S78 - S78
  • [45] Consolidation Chemotherapy after Concurrent Chemoradiation for Non-Resectable Non-Small Cell Lung Cancer
    Ahn, Sung-Ja
    Kim, Young-Chul
    Kim, Kyu-Sik
    Oh, In-Jae
    Kweon, Sun-Seog
    Yoon, Mi Sun
    Na, Kook-Joo
    Song, Sang-Yun
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S397 - S398
  • [46] First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice
    Kim, Y.
    Sun, J.
    Park, K.
    Park, S. E.
    Lee, S.
    Ahn, M.
    Ahn, J. S.
    Lim, S. W.
    Lee, H.
    Cho, J. H.
    Kim, H. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
  • [47] Neoadjuvant chemoradiation in non-small cell lung cancer
    Girard, N.
    Hennequin, C.
    Mornex, F.
    ONCOLOGIE, 2007, 9 (06) : 475 - 481
  • [48] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen
    Jin, Feng
    Cheng, Boran
    Zhang, Yue
    Zhou, Qing
    Wang, Shubin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (07) : 1721 - 1735
  • [49] Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer
    McCall, Neal S.
    Janopaul-Naylor, James R.
    McGinnis, H. Scott
    Kesarwala, Aparna H.
    Tian, Sibo
    Stokes, William A.
    Shelton, Joseph W.
    Steuer, Conor E.
    Carlisle, Jennifer W.
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    Bradley, Jeffrey D.
    Higgins, Kristin A.
    CANCER, 2023, 129 (23) : 3713 - 3723
  • [50] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Fen Wang
    Feng Jin
    Boran Cheng
    Yue Zhang
    Qing Zhou
    Shubin Wang
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1721 - 1735
12345